MedTrace Logo

Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS

NCT02452216 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-08-31

No results posted yet for this study

Summary

This pilot clinical trial study will assess the inflammatory response of brain tumors or other central nervous system conditions in pediatric and adult patients using ferumoxytol-enhanced MRI. Imaging features will be correlated with the number of inflammatory cells (macrophages) at histopathology. Determining the extent of inflammation associated with pathologies in the central nervous system may be helpful for diagnostic and prognostic purposes as well as monitoring treatment response of current and future immunotherapies.

Conditions

  • Brain Injury
  • Central Nervous System Degenerative Disorder
  • Central Nervous System Infectious Disorder
  • Central Nervous System Vascular Malformation
  • Hemorrhagic Cerebrovascular Accident
  • Ischemic Cerebrovascular Accident
  • Primary Brain Neoplasm
  • Brain Cancer
  • Brain Tumors

Interventions

DRUG

Ferumoxytol

Undergo ferumoxytol-enhanced MRI

OTHER

Tissue Analysis

Correlative analysis for macrophage detection and quantification. This applies for all patients in the experimental arm who undergo ferumoxytol infusion.

PROCEDURE

Magnetic Resonance Imaging

All subjects in the experimental arm who undergo ferumoxytol infusion will subsequently have MRI.

Sponsors & Collaborators

  • Michael Iv

    lead OTHER

Principal Investigators

  • Michael Iv, MD · Stanford University Hospitals and Clinics

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-10
Primary Completion
2017-01-12
Completion
2017-01-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02452216 on ClinicalTrials.gov